Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk & The Challenge of Disease Management

Executive Summary

Novo officials found Lilly's acquisition of PCS Health Systems Inc. hard to ignore. Of most immediate concern was the impact that the acquisition would have on the insulin marketplace, given its powerful presence in the US. How and to what extent should Novo respond?

You may also be interested in...



Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts

In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?

Lifescan Accelerates its Dealmaking

Less than a month after the LifeScan subsidiary of Johnson & Johnson said it was buying Inverness Medical Technologies, one of its main suppliers, it solidified another old friendship, this time with Novo Nordisk, the Danish maker of insulin and insulin delivery systems. The two companies announced a global alliance to develop and market a series of diabetes management devices--but withheld details. The two companies had previously teamed up in 1995.

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

IV000426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel